Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.
Mydecine Innovations Group Inc. (MYCO)
le 5 octobre/October 2023
The common shares of Mydecine Innovations Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.